Grifols Launches FDA-Approved Fibrinogen Concentrate FESILTY in U.S.
The plasma-derived concentrate targets a rare bleeding disorder affecting both pediatric and adult patients — a niche b…
The plasma-derived concentrate targets a rare bleeding disorder affecting both pediatric and adult patients — a niche b…
Data from Stockholm congress covers two China-approved oncology assets with implications for global development pipelin…
The MC4R-pathway agonist is under scrutiny as a potential model for appetite-regulating therapeutics at the rare-diseas…
Peer-reviewed data published in a leading transplant journal positions the diagnostic tool as a new clinical benchmark …
Cartilage regeneration biomarkers add mechanistic weight to the joint-health claim, positioning the ingredient for stru…
ALK's EAACI data highlight adherence and administration barriers that a needle-free delivery format could address for a…
A supplemental BLA filing is planned for H2 2026, potentially expanding clinical options in vascular access — a space a…
The milestone marks a formal clinical entry point for a diagnostic approach that could reshape early-detection protocol…
The NK-cell engager approach sits outside core nutraceutical channels, but biotech-to-ingredient crossover investors ar…
Real-world evidence from a matched Medicare cohort signals a meaningful care-pathway shift for lumbar discogenic pain m…
Health systems leaning on telehealth infrastructure could accelerate practitioner-channel nutraceutical recommendations…